natgillin/translations-raw huggingface dataset:
Podatki iz kliničnih preskušanj podpirajo uporabo do 12 mesecev, največjo korist pa so opazili po 3 mesecih (glejte poglavje 5.1). 
Clinical trial data support use up to 12 months, and the maximum benefit was seen at 3 months (seesection 5.1).
so objavljene na spletni strani Evropske agencije za zdravila: http://www.ema.europa.eu/. 
Detailed information on this medicinal product is available on the website of the European Medicines Agency: http://www.ema.europa.eu/.
svojega zdravnika, če jemljete ali ste pred kratkim jemali katero od naslednjih zdravil: 
Talk to your doctor if you are using or have recently used any of the following medicines:
Poleg tega analiza podskupin glede na starost nakazuje, da so koristi klopidogrela pri bolnikih, starejših od 75 let, manjše od tistih, ki so jih opazili pri bolnikih ≤ 75 let. 
In addition, a subgroup analysis by age suggested that the benefit of clopidogrel in patients over 75 years was less than that observed in patients ≤75 years.
Če se pri vas pojavi kateri od sledečih simptomov, se nemudoma posvetujte z zdravnikom: 
If you suffer from any of the following symptoms you should contact your doctor immediately:
Poleg tega varnostne značilnosti klopidogrela v tej podskupini bolnikov niso bile 
Moreover, the safety profile of clopidogrel in this subgroup of patients did not raise any particular concern.
B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE 
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
Ena tableta vsebuje 62,16 mg laktoze monohidrata in 10 mg hidrogeniranega ricinusovega olja. 
Each tablet contains 62.16 mg lactose monohydrate and 10 mg hydrogenated castor oil.
Kemična in fizikalna stabilnost zdravila v HDPE steklenički je bila dokazana za naslednje obdobje: 
For the HDPE bottle presentation chemical and physical in-use stability have been demonstrated for:
Pred uporabo preberite priloženo navodilo. 
Read the package leaflet before use.
C. DRUGI POGOJI ALI ZAHTEVE DOVOLJENJA 
C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
Atrijska fibrilacija 
Atrial fibrillation
TEVA Santé SA Rue Bellocier 89107 Sens Francija 
TEVA Santé SA Rue Bellocier 89107 Sens France
Tableto položitev v usta in jo pogoltnite skupaj z vodo ali drugo tekočino. 
Put the tablet in your mouth and swallow with water or another liquid.
Vendar pa je zaradi pomanjkanja študij o interakcijah z drugimi nesteroidnimi protivnetnimi zdravili trenutno nejasno, ali povečano tveganje za pojav gastrointestinalne krvavitve obstaja pri vseh nesteroidnih protivnetnih zdravilih. 
However, due to the lack of interaction studies with other NSAIDs it is presently unclear whether there is an increased risk of gastrointestinal bleeding with all NSAIDs.
Preiskave 
Investigations
Poleg neželenih učinkov v kliničnih študijah so bile neželene reakcije prijavljene tudi spontano. 
In addition to clinical studies experience, adverse reactions have been spontaneously reported.
Populacijo bolnikov je sestavljalo 19,7 % žensk in 29,2 % bolnikov v starosti ≥ 65 let. 
The patient population included 19.7% women and 29.2% patients ≥65 years.
Ustrezna odmerna shema za to populacijo bolnikov v kliničnih preskušanjih ni bila ugotovljena. 
An appropriate dose regimen for this patient population has not been established in clinical outcome trials.
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJ 
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
TEVA UK Ltd Brampton Road, Hampden Park, Eastbourne, East Sussex, BN22 9AG, Velika Britanija 
TEVA UK Ltd Brampton Road, Hampden Park, Eastbourne, East Sussex, BN22 9AG, United Kingdom
Shranjujte v originalni ovojnini za zagotovitev zaščite pred svetlobo. 
Store in the original package to protect from light.
Med jemanjem tega zdravila ne smete dojiti. 
You should not breastfeed while taking this medicine.
Med tem dolgoročnim spremljanjem niso ugotovili novih 
No new safety concerns were noted during this long-term follow-up.
Analiza skupne umrljivosti kot sekundarnega opazovanega dogodka ni pokazala značilne razlike med klopidogrelom (5,8 %) in acetilsalicilno kislino (6,0 %). 
Analysis of total mortality as a secondary endpoint did not show any significant difference between clopidogrel (5.8%) and ASA (6.0%).
in glavni krožeči (neaktivni) metabolit se in vitro reverzibilno vežeta na humane plazemske proteine (98 % oziroma 94 %). 
Clopidogrel and the main circulating (inactive) metabolite bind reversibly in vitro to human plasma proteins (98% and 94% respectively).
Nosečnost in dojenje Priporočljivo je, da tega zdravila v nosečnosti ne uporabljate. 
Pregnancy and breast-feeding It is preferable not to use this medicine during pregnancy.
Na primer ibuprofen, diklofenak in meloksikam. 
E.g. ibuprofen, diclofenac and meloxicam.
driska, 
It may harm them,
Manj izrazita zmanjšana izpostavljenost presnovkov je bila opažena pri pantoprazolu ali lansoprazolu. 
Less pronounced reductions of metabolite exposure has been observed with pantoprazole or lansoprazole.
TEVA Santé SA, Rue Bellocier, 89107 Sens, Francija 
TEVA Santé SA, Rue Bellocier, 89107 Sens, France
Ko so klopidogrel dajali podganam v obdobju laktacije, je povzročil rahlo upočasnitev razvoja mladičev. 
When given to lactating rats, clopidogrel caused a slight delay in the development of the offspring.
Pri vezavi in vitro ni nasičenja v širokem koncentracijskem razponu. 
The binding is non-saturable in vitro over a wide concentration range.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli, steklenički in pretisnem omotu. 
Do not use this medicine after the expiry date which is stated on the outer carton, bottle or blister after EXP.
Študiji ACTIVE-W in ACTIVE-A, ločeni preskušanji v programu ACTIVE, sta vključili bolnike z atrijsko fibrilacijo (AF), ki so imeli vsaj en dejavnik tveganja za žilne dogodke. 
The ACTIVE-W and ACTIVE-A studies, separate trials in the ACTIVE program, included patients with atrial fibrillation (AF) who had at least one risk factor for vascular events.
Klopidogrel podaljša čas krvavitve in ga je potrebno uporabljati previdno pri bolnikih z lezijami, ki so nagnjene h krvavitvi (zlasti gastrointestinalne in intraokularne). 
Clopidogrel prolongs bleeding time and should be used with caution in patients who have lesions with a propensity to bleed (particularly gastrointestinal and intraocular).
zmedenost in halucinacije, 
Confusion or hallucinations
Citokrom P450 2C19 (CYP2C19) 
Cytochrome P450 2C19 (CYP2C19)
Učinka na delež ponovnih hospitalizacij zaradi nestabilne angine niso opazili. 
There was no observed effect on the rate of rehospitalisation for unstable angina.
Vseeno sočasna uporaba 500 mg acetilsalicilne kisline dvakrat na dan en dan ni pomembno povečala podaljšanja časa krvavitve, sprožene z jemanjem klopidogrela. 
However, concomitant administration of 500 mg of ASA twice a day for one day did not significantly increase the prolongation of bleeding time induced by clopidogrel intake.
Pharmachemie B.V. Swensweg 5, 2031 GA Haarlem, Nizozemska 
Pharmachemie B.V. Swensweg 5, 2031 GA Haarlem, The Netherlands
Ko so slabi metabolizatorji prejemali shemo 600 mg/150 mg, je bila izpostavljenost aktivnemu presnovku večja kot s shemo 300 mg/75 mg. 
When poor metabolisers received the 600 mg/150 mg regimen, active metabolite exposure was greater than with the 300 mg/75 mg regimen.
Če ste imeli alergijo ali alergijsko reakcijo na katero koli zdravilo, ki ste ga jemali. 
• You have had an allergy or reaction to any medicine used to treat your disease.
Ker kliničnih podatkov o izpostavljenosti klopidogrelu med nosečnostjo ni, je kot previdnostni ukrep zaželeno, da se klopidogrela v nosečnosti ne uporablja. 
As no clinical data on exposure to clopidogrel during pregnancy are available, it is preferable not to use clopidogrel during pregnancy as a precautionary measure.
V študiji relativne biološke uporabnosti pri odraslih je imela pripravljena raztopina klopidogrela podoben obseg in rahlo večjo hitrost absorpcije glavnega krožečega (neaktivnega) presnovka kakor odobrena tableta. 
In a relative bioavailability study in adults, the constituted solution of clopidogrel showed a similar extent and slightly higher rate of absorption of the main circulating (inactive) metabolite compared to the authorised tablet
- Stekleničke vsebujejo 30 ali 100 filmsko obloženih tablet. 
- Bottles contain 30 or 100 film-coated tablets.
Agregacija trombocitov in čas krvavitve sta se postopoma vrnila na izhodiščno vrednost, na splošno v 5 dneh po ukinitvi zdravljenja. 
Platelet aggregation and bleeding time gradually returned to baseline values, generally within 5 days after treatment was discontinued.
ZA SPROŠČANJE SERIJ B. POGOJI ALI ZAHTEVE GLEDE OSKRBE IN UPORABE C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA 
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING
Ni znano ali se klopidogrel pri človeku izloča v materino mleko. 
It is unknown whether clopidogrel is excreted in human breast milk.
svojega zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katerokoli zdravilo, tudi če ste ga dobili brez recepta. 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.
Če ste noseči ali sumite, da ste noseči, morate o tem obvestiti svojega zdravnika ali farmacevta, preden vzamete zdravilo Klopidogrel Teva Pharma B.V.. 
If you are pregnant or suspect that you are pregnant, you should tell your doctor or your pharmacist before taking Clopidogrel Teva Pharma B.V.
Približno 88 % bolnikov je sočasno prejemalo acetilsalicilno kislino (v razponu od 1 do 23 mg/kg/dan). 
Approximately 88% of patients received concomitant ASA (range of 1 to 23 mg/kg/day).
In vitro poteka ta presnovna pot s CYP3A4, CYP2C19, CYP1A2 in CYP2B6. 
In vitro, this metabolic pathway is mediated by CYP3A4, CYP2C19, CYP1A2 and CYP2B6.
• heparin (zdravilo, ki se uporablja za preprečevanje strjevanja krvi). 
• Heparin (medicine used to prevent blood clotting).
V podskupini z miokardnim infarktom je večina bolnikov prejemala acetilsalicilno kislino prvih nekaj dni po akutnem miokardnem infarktu. 
In the myocardial infarction subgroup, most of the patients received ASA for the first few days following the acute myocardial infarction.
Antacidi niso spremenili obsega absorpcije klopidogrela. 
Antacids did not modify the extent of clopidogrel absorption.
Nedavni miokardni infarkt (MI), nedavna kap ali ugotovljena periferna arterijska bolezen 
Recent myocardial infarction (MI), recent stroke or established peripheral arterial disease
Za vse morebitne informacije o tem zdravilu se lahko obrnete na predstavništvo imetnika dovoljenja za promet z zdravilom. 
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Razen zgoraj navedenih podatkov o specifičnih interakcijah z zdravili, študij o interakcijah klopidogrela z nekaterimi drugimi zdravili, ki jih bolniki z aterotrombotično boleznijo pogosto uporabljajo, niso izvedli. 
Apart from the specific medicinal product interaction information described above, interaction studies with clopidogrel and some medicinal products commonly administered in patients with atherothrombotic disease have not been performed.
Če vam je zdravnik povedal, da imate intoleranco za nekatere sladkorje, se pred uporabo tega zdravila posvetujte 
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.
Jemanje teh zdravil v kombinaciji z zdravilom Klopidogrel Teva Pharma B.V. lahko poveča tveganje za pojav krvavitev. 
Taking these medicines in combination with Clopidogrel Teva Pharma B.V. could result in an increased risk of bleeding.
če ste alergični na klopidogrel ali katerokoli sestavino tega zdravila (navedno v poglavju 6). 
• If you are allergic (hypersensitive) to clopidogrel or any of the other ingredients of this medicine (listed in section 6).
Pri slabih metabolizatorjih je bila izpostavljenost aktivnemu presnovku za 63 do 71 % manjša kot pri dobrih metabolizatorjih. 
In poor metabolisers, active metabolite exposure was decreased by 63-71% compared to extensive metabolisers.
V nekliničnih študijah pri podganah in pavijanih so bili najpogosteje opaženi neželeni učinki jetrne spremembe. 
During non clinical studies in rat and baboon, the most frequently observed effects were liver changes.
s CYP2C19 so približno 2% pri Kavkazijcih, 4% pri črncih in 14% pri Kitajcih. 
Published frequencies for the poor CYP2C19 metaboliser genotypes are approximately 2% for Caucasians, 4% for Blacks and 14% for Chinese.
NSAIDs: v klinični študiji, ki je bila izvedena pri zdravih prostovoljcih, je sočasna uporaba klopidogrela in naproksena povečala prikrito izgubo krvi iz prebavil. 
NSAIDs: in a clinical study conducted in healthy volunteers, the concomitant administration of clopidogrel and naproxen increased occult gastrointestinal blood loss.
EU/1/10/649/001-016 
MARKETING AUTHORISATION NUMBER(S) EU/1/10/649/001-016
• vnetje v ustih (stomatitis), 
Sore mouth (stomatitis)
Preprečevanje aterotrombotičnih dogodkov: Klopidogrel je indiciran pri: 
Prevention of atherothrombotic events Clopidogrel is indicated in:
Sestavljeni opazovani dogodki so bili smrt zaradi kateregakoli vzroka ali prvi pojav ponovnega infarkta, kapi ali smrt. 
The co-primary endpoints were death from any cause and the first occurrence of re-infarction, stroke or death.
Če ste vzeli večji odmerek zdravila Klopidogrel Teva Pharma B.V., kot bi smeli Če vi (ali kdorkoli drug) meni, da ste pomotoma vzeli preveliko število tablet ali mislite, da jih je pogoltnil otrok, nemudoma obiščite najbližji oddelek nujne medicinske pomoči ali o tem nemudoma obvestite 
If you take more Clopidogrel Teva Pharma B.V. than you should If you (or someone else) swallow a lot of the tablets all together, or if you think a child has swallowed any of the tablets, contact your nearest hospital casualty department or your doctor immediately.
Akutni koronarni sindrom 
Acute coronary syndrome
Občasna uporaba acetilsalicilne kisline (ne več kot 1.000 mg v obdobju 24 ur) na splošno ne povzroča težav, vendar 
An occasional use of acetylsalicylic acid (no more than 1,000 mg in any 24 hour period) should generally not cause a problem, but prolonged use in other circumstances should be discussed with your doctor.
spremembe ravni določenih snovi v krvi ali urinu. To je mogoče ugotoviti 
Changes in levels of certain substances in your blood or urine.
Rezultati te podskupine se torej skladajo 
Thus, the results from this subset are in line with the overall trial results.
Ugotovili so, da klopidogrel nima nobenega učinka na plodnost podganjih samcev in samic ter da ni teratogen pri podganah ali kuncih. 
Clopidogrel was found to have no effect on the fertility of male and female rats and was not teratogenic in either rats or rabbits.
Ne vzemite dvojnega odmerka, da bi nadomestili posamezne izpuščene odmerke. 
Do not take a double dose to make up for a forgotten tablet.
Običajni odmerek je ena 75 mg tableta na dan, ki jo zaužijete z vodo ali drugo tekočino. 
The recommended dose is one 75 mg tablet per day which should be swallowed with water or another liquid.
Če je potrebno takojšnje korigiranje podaljšanega časa krvavitve, lahko s transfuzijo trombocitov dosežemo nasprotni učinek klopidogrela. 
If prompt correction of prolonged bleeding time is required, platelet transfusion may reverse the effects of clopidogrel.
s spojem in prvo uporabo raziskovanega zdravila je bil 20 dni. 
The mean time between shunt palliation and first administration of study medicinal product was 20 days.
Redki 
Rare
V študijah CURE, CLARITY, ACTIVE-A in eni od kohortnih študij (Trenk) niso odkrili večjega deleža dogodkov glede na metabolizatorsko stanje. 
In CURE, CLARITY, ACTIVE-A and one of the cohort studies (Trenk), no increased event rate was observed based on metaboliser status.
Heparin: v klinični študiji, ki je bila izvedena pri zdravih osebah, uporaba klopidogrela ni pomenila spremembe odmerka heparina ali spremembe učinka heparina na koagulacijo. 
Heparin: in a clinical study conducted in healthy subjects, clopidogrel did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.
Bolniki z redko dedno intoleranco za galaktozo, laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcijo glukoze/galaktoze ne smejo jemati tega zdravila. 
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
DATUM ZADNJE REVIZIJE BESEDILA <{DD. 
DATE OF REVISION OF THE TEXT <DD month YYYY>
Populacijo bolnikov je sestavljalo 27,8 % žensk, 58,4 % bolnikov starih ≥ 60 let (2 % ≥ 70 let ) in 54,5 % bolnikov, ki so prejemali fibrinolitike. 
The population included 27.8% women, 58.4% patients ≥60 years (26% ≥70 years) and 54.5% patients who received fibrinolytics.
Pri bolnikih z akutnim miokardnim infarktom z elevacijo ST spojnice sta bili varnost in učinkovitost klopidogrela vrednoteni v dveh randomiziranih, s placebom kontroliranih, dvojno slepih študijah, CLARITY in COMMIT. 
In patients with acute ST-segment elevation MI, safety and efficacy of clopidogrel have been evaluated in 2 randomised, placebo-controlled, double-blind studies, CLARITY and COMMIT.
karbamazepin ali oksakarbazepin, zdravila za zdravljenje nekaterih oblik epilepsije, 
• Carbamazepine, or oxcarbazepine, medicines to treat some forms of epilepsy.
Posebne farmakokinetične študije, ki so jih opravili z radioaktivno označenim klopidogrelom, so pokazale, da se izvorna spojina ali njeni presnovki izločajo v mleko. 
Specific pharmacokinetic studies performed with radiolabelled clopidogrel have shown that the parent compound or its metabolites are excreted in the milk.
Triinsedemdeset odstotkov (73 %) bolnikov, vključenih v študijo ACTIVE-A, je bilo neprimernih za prejemanje VKA po zdravnikovi oceni, nezmožnosti upoštevanja kontrol INR (internacionalnega normaliziranega razmerja), nagnjenosti k padcem ali poškodbe glave, ali specifičnega tveganja krvavitev; pri 26 % bolnikov je zdravnikova odločitev temeljila na tem, da bolnik ni želel jemati VKA. 
Seventy-three percent (73%) of patients enrolled into the ACTIVE-A study were unable to take VKA due to physician assessment, inability to comply with INR (international normalised ratio) monitoring, predisposition to falling or head trauma, or specific risk of bleeding; for 26% of the patients, the physician's decision was based on the patient's unwillingness to take VKA.
Ni bilo dokazov o kancerogenem učinku pri dajanju klopidogrela 78 tednov mišim in 104 tedne podganam v odmerkih do 77 mg/kg na dan (kar predstavlja najmanj 25-krat večjo izpostavljenost kot pri človeku pri prejemanju kliničnega odmerka 75 mg/dan). 
There was no evidence of carcinogenic effect when clopidogrel was administered for 78 weeks to mice and 104 weeks to rats when given at doses up to 77 mg/kg per day (representing at least 25 times the exposure seen in humans receiving the clinical dose of 75 mg/day).
Navzkrižne reakcije med tienopiridini 
Cross reactions among thienopyridines
6.6 Posebni varnostni ukrepi za odstranjevanje 
6.6 Special precautions for disposal
Trombolitiki: varnost sočasne uporabe klopidogrela, fibrinsko specifičnih ali fibrinsko nespecifičnih trombolitikov in heparinov je bila ovrednotena pri bolnikih z akutnim miokardnim infarktom. 
Thrombolytics: the safety of the concomitant administration of clopidogrel, fibrin or non-fibrin specific thrombolytic agents and heparins was assessed in patients with acute myocardial infarction.
Študije pri živalih so pokazale, da se klopidogrel izloča v mleko. 
Animal studies have shown excretion of clopidogrel in breast milk.
ste doživeli hudo obliko bolečine v prsih, znano kot “nestabilna angina” ali “miokardni infarkt” (srčni napad). 
• You have experienced a severe type of chest pain known as ‘unstable angina' or ‘myocardial infarction' (heart attack).
Na podlagi meril za vključitev so zdravniki bolnike vključili v ACTIVE-W, če so bili kandidati za zdravljenje z antagonistom vitamina K (VKA), npr. z varfarinom. 
Based on enrollment criteria, physicians enrolled patients in ACTIVE-W if they were candidates for vitamin K antagonist (VKA) therapy (such as warfarin).
Poročali so o naslednjih neželenih učinkih. 
The following side effects have been reported.
splošne alergijske reakcije (na primer, splošni občutek toplote z nenadnim nelagodjem do nezavesti); težave pri dihanju, otekanje ali vnetje v ustih, kožne alergije, mehurji na koži, 
Generalised allergic reactions (for example, overall sensation of heat with sudden general discomfort until fainting); breathing difficulties, swelling or inflammation of the mouth, skin allergy, blisters on the skin
Farmakogenetika 
Pharmacogenetics
Ime in naslov izdelovalca (izdelovalcev), odgovornega (odgovornih) za sproščanje serije 
Name and address of the manufacturer(s) responsible for batch release
če imate zdravstveno stanje, ki trenutno povzroča krvavitev, kot je želodčna razjeda ali krvavitev v možganih. 
• If you are suffering from another condition which is currently causing bleeding such as a stomach ulcer or bleeding within the brain.
To je veljalo za vse podskupine bolnikov, opredeljene z določenimi izhodiščnimi značilnostmi in tipom fibrinolitičnega ali heparinskega zdravljenja. 
This was consistent across subgroups of patients defined by baseline characteristics, and type of fibrinolytic or heparin therapy.
Izkušnje so omejene pri bolnikih z zmerno jetrno boleznijo, ki imajo lahko hemoragično diatezo. 
Experience is limited in patients with moderate hepatic disease who may have bleeding diatheses.
To zdravilo vsebuje hidrogenirano ricinusovo olje, ki lahko povzroči želodčne težave in drisko. 
This medicinal product contains hydrogenated castor oil which may cause stomach upset and diarrhoea.
Povprečna starost je bila 71 let, 41,6 % bolnikov je bilo 
The mean age was 71 years, 41.6% of patients were ≥75 years.
V celoti je 23,0 % bolnikov prejemalo antiaritmike, 52,1 % blokatorje beta, 54,6 % zaviralce ACE in 25,4 % statine. 
A total of 23.0% of patients received anti-arrhythmics, 52.1% beta-blockers, 54.6% ACE inhibitors, and 25.4% statins.
Ta koristni učinek se je pojavljal v vseh podskupinah, ki so bile predhodno opredeljene glede na bolnikovo starost ali spol, mesto infarkta in tip uporabljenega fibrinolitika ali heparina. 
This benefit was consistent across all prespecified subgroups including patients' age and gender, infarct location, and type of fibrinolytic or heparin used.
V stanju dinamičnega ravnovesja je bila povprečno opažena raven zaviranja z odmerkom 75 mg na dan med 40 % in 60 %. 
At steady state, the average inhibition level observed with a dose of 75 mg per day was between 40% and 60%.
Klinično pomembni neželeni učinki, zabeleženi v študijah CAPRIE, CURE, CLARITY, COMMIT in ACTIVE-A, so predstavljeni spodaj. 
The clinically relevant adverse reactions observed in the CAPRIE, CURE, CLARITY, COMMIT and ACTIVE-A studies are discussed below.
tveganjem za krvavitve, se priporoča, da odmerek ASA ni večji od 100 mg. 
Since higher doses of ASA were associated with higher bleeding risk it is recommended that the dose of ASA should not be higher than 100 mg.
9AG East Sussex 
BN22 9AG East Sussex United Kingdom
veliko zmanjšanje števila določenih krvnih celic, kar vodi do povečanega tveganja za pojav krvavitev ali odrgnin, okužb, bledosti kože in hudo utrujenost, 
Severe reduction in certain blood cells leading to increased risk of bleeding or bruising, increased risk of infections, pale skin and extreme tiredness
Tienopiridini lahko povzročijo blage do hude alergijske reakcije, na primer izpuščaj, angioedem ali hematološke navzkrižne reakcije, naprimer trombocitopenijo in nevtropenijo. 
Thienopyridines may cause mild to severe allergic reactions such as rash, angioedema, or haematological cross-reactions such as thrombocytopaenia and neutropaenia.